Scott C. Weaver

TL;DR: The duration and scope of the recent Mexican epizootics were limited by lack of equine amplification characteristic of previous, more extensive VEE outbreaks, which may have resulted from the circulation of a more equine-neurotropic, subtype IE virus strain or from increased transmission to horses due to amplification by other vertebrate hosts or transmission by more competent mosquito vectors.

TL;DR: In this paper, vector competence of wild-type, urban, and non-urban Aedes aegypti and Ae. vittatus from Senegal and Cape Verde for chikungunya virus (CHIKV) was investigated.

TL;DR: It is demonstrated that the IRES-based VEEV vaccine’s ability to protect against febrile disease in cynomolgus macaques was well tolerated and elicited robust neutralizing antibody titers noticed as early as day 14.

TL;DR: It is suggested that CHIKV infection can confer cross-protective effects against MAYV, and the resultant reduction in viremia may limit the emergence potential of MAYV.

TL;DR: The hamster results confirm clinical evidence that the D614G mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increases transmission and antibody neutralization, and suggest therapeutic antibodies should be tested against the circulating G614 virus before clinical development.